ª½¨ìªñ¦~¡ADLBCLªº°_©lªvÀø¦³¤F·sªºÂà¾÷¡C¦pªG¯f±w¤@¶}©l³Q¶EÂ_®É¡A¸gIPI scoreµû¶q¤À¼Æ¸¨¦b2¤À¥H¤W¡A±µ¨ü·sªº§ÜÅé-ÃĪ«½Æ¦XÅéantibody-drug conjugate (ADC) ¡Gpolatuzumab vedotin¡A»P§ÜCD20³æ®è§ÜÅé¡GRituximab¡A¤Î¤ÆÀøªº²Õ¦X¡]Pola-R CHP¡^¡A¯à¦³¸û¦nªº¯e¯f¤ÏÀ³²v¡C©Ò¿×IPI¡]international prognostic index¡^score¬O¥H¦~ÄÖ¡BÅé¯àª¬ºA¡B¤À´Á¤ÎLDH«ü¼Æ¡B²O¤Ú¸¢¥~«I¥Çµ¥5¶µ¤À¼Æ¨Ópºâ¹w«á¡A¤À¼Æ¶V°ªªí¥Ü¹w«á¶V®t¡C
®Ú¾ÚPOLARIX trial¡A III´Á¦h¤¤¤ßÂùª¼Á{§É¸ÕÅçÅã¥Ü¡A¥HPola-R CHP¬°°_©lªvÀø¡A¬Û¸û©ó¶Ç²Î¼Ð·ÇR-CHOPªvÀø¡A¦b¨â¦~ªº°lÂÜ´Á¶¡¡A¯f¤HªºµL¯e¯f´c¤Æ¦s¬¡²v¥i(progression free survival, PFS) ±q70.2%¤W¤É¨ì76.7%¡C¡v
´N«ez¯f±w¬°¨Ò¡Aªü§BªºIPI¤À¼Æ¬°3¡AÄÝ©ó¹w«á¤£¦nªº¯f±w¡A¦b¸g¹L°Q½×«á¨M©w¨Ï¥ÎPola-R CHPªvÀø¤è¦¡¡A¥Ø«eÀøµ{µ²§ô¬°§¹¥þ½w¸Ñª¬ªp¡A¥u¶·©w´Á¦^¶E¡A¥Í¬¡¤@¤Á¦p±`¡C
¦o©IÆ~¡ADLBCLªº±`¨£¯gª¬¤´¥H²O¤Úµ²¸~¤j¬°¥D¡A¦p¦³µo²{¸~¶ô«ùÄòÅܤj¡A¥B¦ñÀH¦³Åé«´î»´¡Bµs¦½¡B¹¼¤¤£®¶®Én¤Î¦½Ð¨DÂåÀø¨ó§U¡A¶i¤@¨B°µ¤Á¤ù¶EÂ_¡A¿n·¥ªvÀø¡A¥HÀò±o³Ì¦nªºªvÀø®ÄªG¡C
¥»¤å¸g °·±dÂåÀøºô ±ÂÅv¥Zµn¡Aì¤åµoªí
©ó¦¹
¡i°·±dÂåÀøºô¡þ°OªÌ¤ý«a§Ê³ø¾É¡j2023/12/06